Revenue
2019
2020
2021
2022
2023
2024
2025
TREACE MEDICAL CONCEPTS, INC. (TMCI)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $212.7M | $209.4M | $187.1M | $141.8M | $94.4M | $57.4M | $39.4M |
| Gross profit | $169.8M | $168.3M | $151.9M | $116.3M | $77.5M | $44.9M | $31.8M |
| Research & development | $20.3M | $20.6M | $15.4M | $13.6M | $10.2M | $5.8M | $5.1M |
| Operating expenses | $223.9M | $224.0M | $203.4M | $151.2M | $94.0M | $44.0M | $35.3M |
| Operating income | −$54.2M | −$55.7M | −$51.4M | −$34.8M | −$16.5M | $855,000 | −$3.5M |
| EBITDAderived | −$43.5M | −$47.3M | −$46.1M | −$32.7M | −$15.8M | $2.1M | −$2.7M |
| Net income | −$59.0M | −$55.7M | −$49.5M | −$42.8M | −$20.6M | −$3.7M | −$4.3M |
| Basic EPSper diluted share | -$0.93 | -$0.90 | -$0.81 | -$0.77 | -$0.43 | -$0.12 | -$0.13 |
| Diluted EPSper diluted share | -$0.93 | -$0.90 | -$0.81 | -$0.77 | -$0.43 | -$0.12 | -$0.13 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 11, 2026Form 4/A | Treace John T.Chief Executive Officer | BuyCommon Stock | 9.9K | $4.04 | $40.0K | 7.35M |
| Jun 11, 2026Form 4 | Treace John T.Chief Executive Officer | BuyCommon Stock | 22.9K | $4.04 | $92.5K | 7.38M |
| Jun 10, 2026Form 4/A | Treace John T.Chief Executive Officer | BuyCommon Stock | 14.7K | $4.02 | $59.2K | 7.34M |
| Jun 10, 2026Form 4 | Treace John T.Chief Executive Officer | BuyCommon Stock | 29.4K | $4.02 | $118.3K | 7.35M |
| Jun 1, 2026Form 4 | Treace John T.Chief Executive Officer | BuyCommon Stock | 50.0K | $3.56 | $178.0K | 7.32M |